Josh helps entrepreneurs build their businesses and advises them on significant transactions in the life cycle of their companies, with a particular focus on fundraising transactions and exit events.

He represents founders, start-ups, and emerging companies, serving as general counsel to those start-ups and emerging companies. Josh advises clients regarding company formation and early-stage legal issues, a broad range of financings, including angel, venture capital, and strategic investments, and mergers and acquisitions. He also provides guidance on legal and business matters that arise in the daily operations of their businesses.

Josh typically works with companies in the life sciences industry — drug development, devices, diagnostics, and tools — and in the technology sector, including energy, digital health, software, and technology-enabled services. He has helped numerous clients, including the following, to grow and thrive:

• Aquinnah Pharmaceuticals
• Asimov
• Axoft
• Bilayer Therapeutics
• Droplette
• Hopewell Therapeutics
• InGel Therapeutics
• Limax Biosciences
• MediSix Therapeutics
• NanoView Biosciences
• NextGen Jane
• New Equilibrium Biosciences
• PanTher Therapeutics
• Quaise Energy
• Stemloop
• Suono Bio
• Syntis Bio
• Teal Bio
• Verseau Therapeutics

In addition to counseling entrepreneurs and emerging companies, Josh represents venture capital firms, foundations, and other investors.

Josh frequently speaks about topics related to entrepreneurship, financing, exit strategies, and best practices for businesses. He has also been a lecturer at the Boston University School of Law, teaching a class on venture capital financings that he created.

Josh maintains an active pro bono practice and is involved in the firm’s operations, including hiring activities.